Form 4: DENTSPLY SIRONA Director Leslie Varon Receives Equity Grant

DENTSPLY SIRONA Inc. Director Leslie F. Varon was granted 13,880 Restricted Stock Units (RSUs) on May 22, 2025, as part of her compensation.

Summary

• Leslie F. Varon, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 13,880 shares of common stock on May 22, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) with a price of $0 per unit.
• These RSUs are scheduled to vest in full one year from the grant date.
• Following this transaction, Ms. Varon's beneficial ownership in DENTSPLY SIRONA Inc. stands at 47,687.066 shares.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a routine compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction indicates ongoing commitment and compensation for a key board member.

Risks

• The value of the RSU grant is subject to the future performance of DENTSPLY SIRONA's stock price; if the stock price declines, the value of the vested units will also decrease.
• RSUs typically have vesting conditions, and if these conditions (e.g., continued service) are not met, the units may be forfeited.

Future Outlook

The 13,880 Restricted Stock Units granted to Leslie F. Varon are expected to vest in full one year from the grant date, which is May 22, 2026.

Industry Context

Insider equity grants, such as Restricted Stock Units, are a common form of compensation for directors and executives across various industries, including the dental products and technology sector where DENTSPLY SIRONA operates. These grants are designed to incentivize long-term performance and align the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across publicly traded companies, including peers in the medical device and dental supply industries such as Align Technology (ALGN) or Henry Schein (HSIC), which also utilize equity-based incentives to attract and retain talent and align interests.
• The vesting period of one year for these RSUs is a common structure for director grants, promoting retention and long-term commitment.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Director (Leslie F. Varon): Receives equity compensation, which vests over time, providing a direct financial incentive tied to the company's long-term success.

Next Steps

• The Restricted Stock Units are expected to vest in full one year from the grant date (May 22, 2025), at which point they will convert into common stock.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership